Skip to main content

Association of Anti-Mullerian Hormone(AMH)and recurrent pregnancy loss

Tuesday, September 23, 2014 — Poster Session III

12:00 p.m. – 2:00 p.m.

FAES Academic Center



* FARE Award Winner


  • S.M. Zarek
  • E.F. Schisterman
  • E.M. Mitchell
  • R.M. Silver
  • J
  • H
  • Segars
  • S.L. Mumford


Objective: The objective was to assess a possible association between preconception AMH levels with pregnancy loss. Design: Secondary analysis of a multicenter, block-randomized, double-blind, placebo-controlled clinical trial. Materials and Methods: 1228 women attempting pregnancy, aged 18–40 years were block-randomized by center in a 1:1 ratio to preconception-initiated daily low-dose aspirin or placebo. The primary outcome was pregnancy loss (defined as chemical or clinical loss, < 20 weeks gestation). Relative Risk (RR) and 95% confidence intervals (CIs) for pregnancy loss by AMH categories were estimated using generalized linear models adjusted for age. Results: After adjusting for age, women with low (<1.25 ng/mL) versus normal AMH levels had an increased risk of pregnancy loss (RR=1.7, 95% CI 1.1, 2.6) whereas women with high AMH (>4.0 ng/mL) had no significant increased risk of pregnancy loss compared to women with normal AMH levels (RR= 1.2, 95% CI 0.78,1.7). Conclusions: Low AMH levels were associated with higher pregnancy loss, suggesting a woman with low AMH who is able to achieve pregnancy may require counseling for increased risk of subsequent loss. To our knowledge, this is the first report of a significant association between AMH levels and pregnancy loss among women with normal fertility.

back to top